Neurorx

Neurorx company information, Employees & Contact Information

Explore related pages

Related company profiles:

NeuroRx is dedicated to working with the pharmaceutical industry to facilitate clinical trials of new drugs for multiple sclerosis (MS) and other neurological diseases. NeuroRx provides professional management of all MRI-related study activities and promptly delivers precise MRI outcome measurements that are performed in a regulatory compliant environment. We are specialized in logistics of scan handling and tracking and can provide this service exclusively, if needed. NeuroRx uses advanced image analysis techniques to provide precise outcome data that maximize study power. Images are corrected for inhomogeneity and co-registered for perfect re-alignment and increased precision. Analyses are conducted in 3D, rather than on slices, so that information can be properly related to structures that span multiple slices. Customized automatic segmentation techniques are combined with expert supervision to maximize the precision of outcome measures related to both lesional and non-lesional pathology, as well as brain volume changes (atrophy).

Company Details

Employees
81
Address
3575 Avenue Du Parc, Suite #5322,canada
Phone
+1 514 906 3909
Email
in****@****orx.com
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Keywords
Montreal.
HQ
Montreal, Quebec
Looking for a particular Neurorx employee's phone or email?

Neurorx Questions

News

Clario announces acquisition of imaging provider NeuroRx - PR Newswire

Clario announces acquisition of imaging provider NeuroRx PR Newswire

NeuroRx in its acquisition by Clario - Norton Rose Fulbright

NeuroRx in its acquisition by Clario Norton Rose Fulbright

Clario continues acquisition spree with imaging specialist NeuroRx - Fierce Biotech

Clario continues acquisition spree with imaging specialist NeuroRx Fierce Biotech

PE-backed Clario picks up medical research biz NeuroRx - pehub.com

PE-backed Clario picks up medical research biz NeuroRx pehub.com

NeuroRx’s RLF-100: the key to treating and preventing Covid-19 respiratory failure? - Pharmaceutical Technology

NeuroRx’s RLF-100: the key to treating and preventing Covid-19 respiratory failure? Pharmaceutical Technology

NeuroRx’s Zyesami reduces hospital time in Covid-19 trial - Clinical Trials Arena

NeuroRx’s Zyesami reduces hospital time in Covid-19 trial Clinical Trials Arena

Clario acquires NeuroRx - AuntMinnie

Clario acquires NeuroRx AuntMinnie

NeuroRx completes merger with SPAC, starts trading on Nasdaq - Drug Delivery Business

NeuroRx completes merger with SPAC, starts trading on Nasdaq Drug Delivery Business

Israeli Pharma Firm NeuroRx Completes SPAC Merger at $1.5B Valuation - NoCamels

Israeli Pharma Firm NeuroRx Completes SPAC Merger at $1.5B Valuation NoCamels

NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development - Delco Times

NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development Delco Times

NeuroRx on the Move: An Interview with Founder and CEO Jonathan Javitt - BioSpace

NeuroRx on the Move: An Interview with Founder and CEO Jonathan Javitt BioSpace

RLF-100 (aviptadil) trial shows rapid recovery in Covid-19 patients - Clinical Trials Arena

RLF-100 (aviptadil) trial shows rapid recovery in Covid-19 patients Clinical Trials Arena

NeuroRx plans pivotal trial after seeing hints of efficacy in suicidal patients - Fierce Biotech

NeuroRx plans pivotal trial after seeing hints of efficacy in suicidal patients Fierce Biotech

NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 - PR Newswire

NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 PR Newswire

NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA) - PR Newswire

NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA) PR Newswire

NeuroRx Initiates Phase 2/3 Study of Inhaled ZYESAMI™ for Severe COVID-19 with UCI Health - PR Newswire

NeuroRx Initiates Phase 2/3 Study of Inhaled ZYESAMI™ for Severe COVID-19 with UCI Health PR Newswire

NeuroRx Secures HK$ 750 Million Capital Commitment From The Gem Group for Development of NRX-101 - PR Newswire

NeuroRx Secures HK$ 750 Million Capital Commitment From The Gem Group for Development of NRX-101 PR Newswire

NeuroRx: Phase 3 Drug for Suicidal Bipolar Depression to Present at BIO CEO Conference - PR Newswire

NeuroRx: Phase 3 Drug for Suicidal Bipolar Depression to Present at BIO CEO Conference PR Newswire

NeuroRx and Big Rock Partners Complete $500M Merger - The SPAC Conference

NeuroRx and Big Rock Partners Complete $500M Merger The SPAC Conference

Blind blur assessment of MRI images using parallel multiscale difference of Gaussian filters - BioMedical Engineering OnLine

Blind blur assessment of MRI images using parallel multiscale difference of Gaussian filters BioMedical Engineering OnLine

NeuroRX completes SPAC merger at $1.5b valuation - Globes - Israel Business News

NeuroRX completes SPAC merger at $1.5b valuation Globes - Israel Business News

Top Neurorx Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant